There will be no new names in the pharma industry’s top 20 companies, despite vigorous knocking at the door from growth companies like Biogen, Celgene, Mylan and Shire (replete with its Baxalta acquisition).
Based on projected drug sales for 2016, Pfizer Inc. will remain the top seller of prescription drugs for FY...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?